NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free GERN Stock Alerts $3.73 +0.04 (+1.08%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$3.61▼$3.8050-Day Range$1.75▼$3.7752-Week Range$1.64▼$4.05Volume8.21 million shsAverage Volume10.11 million shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/APrice Target$5.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Geron alerts: Email Address Geron MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside43.0% Upside$5.33 Price TargetShort InterestHealthy8.53% of Shares Sold ShortDividend StrengthN/ASustainability-2.80Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector283rd out of 910 stocksPharmaceutical Preparations Industry121st out of 421 stocks 3.5 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGeron has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.53% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Geron has recently decreased by 8.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a -35.24% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -2.80. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Geron this week, compared to 4 articles on an average week.Search InterestOnly 26 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.34) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -11.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -11.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 8.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Geron Stock (NASDAQ:GERN)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More GERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERN Stock News HeadlinesApril 18, 2024 | businesswire.comGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 13, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Rating Reiterated by Needham & Company LLCApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 11, 2024 | seekingalpha.comConsidering The Merits Of A Gamble On Geron CorporationApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Geron Following Insightful Leadership Discussion and Promising Drug Development ProgressApril 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Carl Zeiss Meditec (GB:0DHC), Geron (GERN) and Zur Rose Group AG (Six Swiss: CH:DOCM)April 11, 2024 | finance.yahoo.comGeron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near FutureApril 3, 2024 | businesswire.comGeron to Participate at Upcoming Investor Conferences in AprilApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.March 27, 2024 | finance.yahoo.comGERN Mar 2024 3.500 putMarch 19, 2024 | markets.businessinsider.comGeron Announces Pricing Of $150 Mln Underwritten Offering Of Common Stock, Pre-Funded WarrantsMarch 19, 2024 | msn.comGeron announces pricing of $150M underwritten offeringMarch 19, 2024 | finance.yahoo.comGeron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMarch 18, 2024 | finance.yahoo.comGERN240517C00003500 (GERN240517C00003500) Interactive Stock Chart - Yahoo FinanceMarch 18, 2024 | finance.yahoo.comGERN240517P00003500 (GERN240517P00003500) Interactive Stock Chart - Yahoo FinanceMarch 16, 2024 | finance.yahoo.comGERN Apr 2024 1.000 putMarch 16, 2024 | finance.yahoo.comGERN Apr 2024 1.500 callMarch 16, 2024 | wsj.comGeron Corp.March 15, 2024 | finance.yahoo.comMDGL Apr 2024 270.000 callMarch 15, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Geron (GERN)March 15, 2024 | msn.comGeron’s stock soars 95% after FDA advisory panel votes in favor of blood-disorder drugMarch 15, 2024 | investorplace.comWhy Is Geron (GERN) Stock Up 94% Today?March 15, 2024 | msn.comBiggest stock movers today: ADBE, GERN, and moreMarch 15, 2024 | seekingalpha.comGeron: Advisory Nod Boosts Approval Odds, But Market Position Remains HazyMarch 15, 2024 | msn.comGeron surges after FDA AdCom backing for lead drugMarch 15, 2024 | markets.businessinsider.comGeron Gets Favorable Votes From FDA Panel For Imetelstat In Treating Transfusion-Dependent AnemiaMarch 14, 2024 | bizjournals.comCancer drug from Peninsula company wins FDA advisory committee thumbs upSee More Headlines Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees141Year FoundedN/APrice Target and Rating Average Stock Price Target$5.33 High Stock Price Target$6.00 Low Stock Price Target$5.00 Potential Upside/Downside+43.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,130,000.00 Net Margins-77,691.14% Pretax Margin-77,690.72% Return on Equity-63.33% Return on Assets-44.71% Debt Debt-to-Equity Ratio0.14 Current Ratio3.16 Quick Ratio3.16 Sales & Book Value Annual Sales$240,000.00 Price / Sales8,499.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book8.11Miscellaneous Outstanding Shares546,870,000Free Float530,468,000Market Cap$2.04 billion OptionableOptionable Beta0.61 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. John A. Scarlett M.D. (Age 73)Chairman of the Board, President & CEO Comp: $1.53MDr. Andrew J. Grethlein Ph.D. (Age 60)Executive VP & COO Comp: $847.2kMs. Michelle J. Robertson (Age 56)Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Ms. Aron FeingoldVice President of Investor Relations & Corporate CommunicationsMr. Scott SamuelsExecutive VP, Chief Legal Officer & Corporate SecretaryMs. Shannon Odam (Age 49)Senior VP & Chief People Officer Ms. Melissa A. Kelly Behrs (Age 60)Executive VP of Business Operations & Chief Alliance Officer Comp: $753.22kMr. Anil Kapur (Age 53)Executive VP of Corporate Strategy & Chief Commercial Officer Comp: $654.89kMr. Edward E. Koval (Age 62)Executive VP & Chief Business Officer Dr. Faye Feller M.D. (Age 41)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXLigand PharmaceuticalsNASDAQ:LGNDIronwood PharmaceuticalsNASDAQ:IRWDMannKindNASDAQ:MNKDChinook TherapeuticsNASDAQ:KDNYView All CompetitorsInsiders & InstitutionsVivo Capital LLCBought 3,081,611 shares on 4/22/2024Ownership: 4.978%Vishria Bird Financial Group LLCBought 3,650 shares on 4/22/2024Ownership: 0.004%Allspring Global Investments Holdings LLCSold 6,962 shares on 4/18/2024Ownership: 0.063%Wellington Management Group LLPSold 920,655 shares on 3/5/2024Ownership: 1.737%Lazari Capital Management Inc.Sold 13,500 shares on 2/27/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions GERN Stock Analysis - Frequently Asked Questions Should I buy or sell Geron stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares. View GERN analyst ratings or view top-rated stocks. What is Geron's stock price target for 2024? 3 equities research analysts have issued 1 year price targets for Geron's shares. Their GERN share price targets range from $5.00 to $6.00. On average, they anticipate the company's stock price to reach $5.33 in the next year. This suggests a possible upside of 43.0% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts. How have GERN shares performed in 2024? Geron's stock was trading at $2.11 on January 1st, 2024. Since then, GERN shares have increased by 76.8% and is now trading at $3.73. View the best growth stocks for 2024 here. Are investors shorting Geron? Geron saw a decrease in short interest in March. As of March 31st, there was short interest totaling 46,660,000 shares, a decrease of 8.4% from the March 15th total of 50,950,000 shares. Based on an average daily trading volume, of 11,240,000 shares, the short-interest ratio is presently 4.2 days. View Geron's Short Interest. When is Geron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our GERN earnings forecast. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) issued its quarterly earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Geron had a negative trailing twelve-month return on equity of 63.33% and a negative net margin of 77,691.14%. The company's quarterly revenue was down 77.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.10) earnings per share. What ETFs hold Geron's stock? ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), WisdomTree BioRevolution Fund (WDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and SPDR S&P Biotech ETF (XBI). What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). Who are Geron's major shareholders? Geron's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (4.98%), Allspring Global Investments Holdings LLC (0.06%) and Vishria Bird Financial Group LLC (0.00%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GERN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
